CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts ≥200 cells/mm3

Antiviral Therapy

Volumn 14, Issue 3, 2009, Pages 451-457

  Guiguet, Marguerite ^a,b   Kendjo, Eric ^a,b   Carcelain, Guislaine ^c   Abgrall, Sophie ^d   Mary Krause, Murielle ^a,b   Tattevin, Pierre ^e   Yazdanpanah, Yazdan ^f   Costagliola, Dominique ^a,b   Duval, Xavier ^g  

^a NSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d AVICENNE HOSPITAL   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f Tourcoing Hospital   (France)

^g BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE; ANTIVIRAL RESISTANCE; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CD8+ T LYMPHOCYTE; CLINICAL EVALUATION; DISEASE COURSE; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; VIRUS LOAD;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 67649191711     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cascade Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
2. Phillips A, Lundgren J. The CD4 lymphocyte count and the risk of clinical progression. Curr Opin HIV AIDS 2006; 1:43-49.
3. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. November 3, 2008 (Updated 3 November 2008. Accessed 29 April 2009.) Available from www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
5. The UK Collaborative HIV Cohort (CHIC) Study Steering Committee. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717-1721.
6. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
7. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? BMJ 2007; 334:76-78.
8. 3. Antivir Ther 2007; 12:941-947.
9. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2001, 133:401-410.
10. Burnham K, Anderson D. Model selection and influence. A practical information-theoretic approach. New York: Springer-Verlag 1998.
11. Kremers WK. Technical report series no 80. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Rochester, MN: Department of Health Sciences Research, Mayo Clinic 2007.
12. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2:114-124.
13. Pirzada Y, Khuder S, Donabedian H. Predicting AIDS-related events using CD4 percentage or CD4 absolute counts. AIDS Res Ther 2006; 3:20.
14. Burcham J, Marmor M, Dubin N, et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5:365-372.
15. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1028-1033.
16. + lymphocytes predict AIDS. AIDS 1999; 13:195-201.
17. Bennet F, Thiebaut R, Cherie G, et al. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy, Aquitaine cohort, France, 1996-2002. HIV Med 2005; 6:198-205.
18. 3. J Infect Dis 2005; 192:950-957.
19. Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cell/μl. HIV Med 2006; 7:383-388.
20. + lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195:425-431.
21. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169:28-36.
22. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165:352-363.
23. Brenner H, Blettner M. Controlling for continuous confounders in epidemiologic research. Epidemiology 1997; 8:429-434.
24. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007; 8:547-554.